Galectin Therapeutics Inc stock is traded at $2.97, with a volume of 114,241. It is down -0.50% in the last 24 hours and down -21.01% over the past month. Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Previous Close:
$2.99
Open:
$3.01
24h Volume:
114,241
Relative Volume:
0.57
Market Cap:
$299.52M
Revenue:
-
Net Income/Loss:
-$26.25M
P/E Ratio:
-
EPS:
-$0.4099
Net Cash Flow:
-$20.05M
1W Performance:
-10.54%
1M Performance:
-21.01%
6M Performance:
+32.00%
1Y Performance:
-46.77%
1-Day Range:
$2.90$3.05
1-Week Range:
$2.90$3.60
52-Week Range:
$2.03$7.13
Galectin Therapeutics Inc Stock (GALT) Company Profile
Name
Galectin Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
678-620-3186Address
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS